Flexsus

What Flexsus does

Flexsus is a privately held, CLIA High Complexity and COLA-accredited molecular diagnostic testing laboratory operating from a single facility at 1275 Kinnear Rd in Columbus, Ohio. The company provides PCR-based diagnostic testing across nine product lines: Coronavirus, GI, Pharyngitis, Respiratory, STI, UTI, Women's Health, Wound, and Pharmacogenomics panels, with a Toxicology Panel listed as 'Coming Soon.' Its core technical platform is polymerase chain reaction (PCR) molecular testing, offering comprehensive pathogen-detection panels (e.g., 17 pathogens/20 assays for GI, 25+ targets for respiratory) with claimed sub-24-hour turnaround and greater than 95% analytical sensitivity and specificity on its Women's Health panel. The laboratory advertises daily capacity exceeding 10,000 tests and delivers results through secure encrypted email (OpenSSL AES-256-CBCL) and a smartphone application.

The company's business model is direct laboratory service revenue from per-test transactions, with no public pricing disclosed. It operates a sales-led go-to-market motion targeting four primary verticals: healthcare providers and OB/GYN clinicians ordering diagnostic panels, employers needing return-to-work testing programs, educational institutions (universities and K-12) requiring campus-wide testing, and sports/event venues such as Arnold Classic. It also serves individual consumers — primarily for travel COVID-19 testing — through a self-serve Square appointment booking integration on the website. Named enterprise clients include Ohio Wesleyan University, eGenesis (CBiotec), Arnold Classic, and Revolution Studios, indicating a small but diversified Ohio-anchored customer base. No funding rounds, headcount, or revenue figures are disclosed, and the company shows no signs of public market activity, M&A, or geographic expansion beyond Ohio. All product imagery and service URLs are dated 2021-2022, suggesting limited recent digital investment.

Name

Flexsus

Legal name

Flexsus

Website

https://goflexsus.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Flexsus is a CLIA High Complexity and COLA-accredited molecular diagnostic laboratory in Columbus, Ohio, offering PCR-based testing panels for healthcare providers, employers, schools, and event venues. It delivers results within 24 hours and has 10,000+ tests per day capacity.

Ownership category

akta.pro rank

Product category

Diagnostic Laboratory Services

NAICS

Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Point-of-Care Testing (POCT) & Near-Patient Labs (HLAFAMAI), Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels) (HLAHAOAJ)

Keywords

• Molecular diagnostic testing
• PCR testing services
• Clinical laboratory testing
• Infectious disease panels
• Pharmacogenomics testing

Headquarters

HQ city

Columbus

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Molecular Diagnostic Testing Services: Flexsus generates revenue through laboratory testing services, providing molecular diagnostic testing panels to healthcare providers, employers, schools, and event venues. Services include Coronavirus, GI, Pharyngitis, Respiratory, STI, UTI, Women's Health, Wound panels, and Pharmacogenomics testing. The company offers appointment-based testing for both individual patients (travel COVID-19) and organizational testing programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Flexsus is an accredited CLIA High Complexity Molecular Testing Laboratory that provides PCR-based diagnostic testing panels (Coronavirus, GI, Pharyngitis, Respiratory, STI, UTI, Women's Health, Wound, Toxicology, and Pharmacogenomics) to healthcare providers, employers, schools, event venues, and individual patients, delivering results within 24 hours through secure digital channels.

Product overview

Flexsus is an accredited CLIA High Complexity Molecular Testing Laboratory offering a comprehensive portfolio of molecular diagnostic testing services. The company provides multiple distinct testing panels including the Coronavirus Panel, GI Panel, Pharyngitis Panel, Respiratory Panel, STI Panel, UTI ID Panel, Women's Panel, and Wound Panel, all utilizing Polymerase Chain Reaction (PCR) molecular technique. Additional services include a Toxicology Panel (Coming Soon) and Pharmacogenomics Panel. The testing services are delivered through a streamlined process with online and smartphone reporting platforms, enabling rapid and accurate results for healthcare providers and patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Coronavirus Panel
• GI Panel 17-pathogen, 20-assay gastrointestinal panel detecting viruses, bacteria, and parasites causing digestive system infections using PCR molecular technique. For healthcare providers treating patients with GI illness.
• Pharyngitis Panel Comprehensive molecular panel detecting the most common viral and bacterial pathogens infecting the throat, supporting diagnosis of pharyngitis and sore throat. For healthcare providers.
• Respiratory Panel Comprehensive molecular panel detecting viral, bacterial, and fungal pathogens causing respiratory illness, including targets for pneumonia and bronchitis. For healthcare providers treating respiratory conditions.
• STI Panel Sexually transmitted infection testing by molecular technique for multiple pathogens including Chlamydia, Gonorrhea, and Herpes. For clinicians and healthcare providers diagnosing STIs.
• UTI ID Panel Comprehensive molecular panel detecting bacterial and yeast urinary pathogens with high sensitivity and specificity compared to traditional urine culture, including pathogens difficult to grow in culture. For healthcare providers diagnosing UTIs.
• Women's Panel OB/GYN molecular diagnostic testing for comprehensive screenings across a broad spectrum of pathogens and genetically influenced conditions, including bacterial vaginosis panels. For OB/GYN clinicians and women's healthcare providers.
• Wound Panel Comprehensive molecular panel detecting the most common pathogens infecting wounds and soft skin, enabling quick management of skin and soft tissue infections and avoiding diagnostic delays. For healthcare providers.
• Pharmacogenomics Panel Comprehensive pharmacogenomics test panels providing insight into a patient's potential response to medications, helping clinicians optimize treatment considerations and outcomes. For healthcare providers prescribing medications.

Quantifiable outcome

• Results delivered within 24 hours or less
• +2 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves12 records

Expansion highlights8 records

Emerging players

• Phosphorus Diagnostics: CLIA-accredited molecular diagnostics laboratory focused on genetic and pharmacogenomic testing for clinicians. Comparable to Flexsus on the pharmacogenomics and women's/genetic-health side of its panel portfolio, though differentiated toward inherited genetic risk rather than infectious disease.
• BillionToOne: Molecular diagnostics company offering PCR/NGS-based prenatal and oncology liquid-biopsy tests from its CLIA-licensed lab. Comparable to Flexsus as a CLIA-accredited molecular lab leveraging proprietary PCR/qPCR technology to address specific clinical niches; differs in market focus but similar regulatory and operational profile.
• Genomics USA: PCR-based molecular diagnostics laboratory that scaled rapidly during the COVID pandemic serving employers, schools, and government testing programs. Closest emerging-player comparable to Flexsus in single-lab, sales-led, organization-focused testing GTM.

Broad incumbents

• Quest Diagnostics: One of the two largest U.S. clinical reference laboratories, offering PCR-based molecular infectious-disease panels (respiratory, GI, STI, UTI), pharmacogenomics, and women's health testing to physicians, hospitals, and employers nationwide. Directly comparable to Flexsus in core molecular test menu and CLIA-regulated lab services, but operates at vastly greater scale and geographic reach.
• ARUP Laboratories: University-affiliated national reference laboratory offering an extensive PCR-based infectious-disease, pharmacogenomics, and women's health testing menu to hospitals and physicians. Comparable to Flexsus in test menu breadth but operates at much larger institutional scale and is owned by the University of Utah.
• Mayo Clinic Laboratories: Hospital-affiliated reference laboratory offering a comprehensive portfolio of molecular infectious-disease, pharmacogenomic, and specialty PCR panels to clients worldwide. Comparable to Flexsus in CLIA High Complexity specialty testing capability but at vastly larger scale and brand authority.
• Laboratory Corporation of America (Labcorp): Major U.S. clinical reference laboratory offering PCR multiplex syndromic panels, pharmacogenomics, and employer/workplace COVID and infectious-disease testing programs. Overlaps directly with Flexsus's panel portfolio and enterprise testing programs but serves a national footprint with hospital and health-system contracts.

Direct peers

• Aegis Sciences Corporation: CLIA-accredited clinical laboratory specializing in toxicology, pharmacogenomics, and PCR-based infectious-disease testing for clinicians, employers, and the司法/criminal justice market. Comparable to Flexsus in CLIA accreditation, multi-panel portfolio (including Flexsus's Toxicology and Pharmacogenomics panels), and clinician-direct GTM motion.
• Mako Medical Laboratories: Mid-sized CLIA-accredited molecular diagnostics laboratory known for PCR-based COVID testing, RT-PCR infectious-disease panels, and workplace/return-to-work testing programs. Closest comparable peer to Flexsus in scale, CLIA High Complexity accreditation, and direct-to-employer/university GTM motion.
• Viracor Eurofins: Specialty clinical molecular diagnostics lab within the Eurofins network performing PCR-based infectious-disease and transplant/immunology testing for hospitals and reference lab clients. Comparable to Flexsus in offering high-complexity molecular panels from a single specialty lab, but with broader clinical reach.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flexsus